Skip to main content
COSMO Pharmaceuticals N.V. logo

COSMO Pharmaceuticals N.V. — Investor Relations & Filings

Ticker · COPN ISIN · NL0011832936 LEI · 724500OX0EBQRYTVV639 SW Manufacturing
Open in API
Filings indexed 169 across all filing types
Latest filing 2025-11-03 Regulatory Filings
Country NL Netherlands
Listing SW COPN

About COSMO Pharmaceuticals N.V.

https://www.cosmopharma.com/

COSMO Pharmaceuticals N.V. is a specialty pharmaceutical company focused on developing and commercializing products in gastroenterology, dermatology, and healthtech. The company's portfolio is built around its proprietary MMX® technology, a platform for the targeted delivery of active ingredients in the colon. Key products include GI Genius™, an AI-powered device for endoscopy; Winlevi®, a topical treatment for acne; and therapies for inflammatory bowel diseases such as Lialda®/Mezavant® and Uceris®/Cortiment®. In addition to its own product pipeline, Cosmo provides contract manufacturing services, including process assessment, technology transfer, stability testing, and market release for pharmaceutical products.

Recent filings

Filing Released Lang Actions
Cosmo Receives CE Certification for ColonPRO EU – The most Advanced AI Software Platform for Colonoscopy in Europe
Regulatory Filings Classification · 100% confidence The document is a press release announcing that Cosmo Pharmaceuticals has received CE certification for its 'ColonPRO EU' AI software. It describes the product features, clinical trial results, and provides a company overview. While it contains an 'Attachments' section at the end, the document itself is a corporate announcement of a regulatory/product milestone, not a report publication announcement (RPA) or a financial report. Since it does not fit into specific categories like earnings, dividends, or governance, it falls under the 'Regulatory Filings' (RNS) category as a general corporate announcement.
2025-11-03 English
Cosmo erhält CE-Zertifizierung für ColonPRO EU – die fortschrittlichste KI-Softwareplattform für Koloskopie in Europa
Regulatory Filings Classification · 100% confidence The document is a press release from Cosmo Pharmaceuticals announcing the receipt of CE certification for their new medical software, ColonPRO EU. It details the product's features, clinical validation, and strategic importance. While it contains a link to a PDF attachment, the text itself is a standalone corporate announcement regarding a product milestone rather than a report publication announcement (RPA) or a regulatory filing (RNS). Since it does not fit into specific financial categories like earnings or dividends, and is a general corporate announcement, it is classified as a Regulatory Filing (RNS) as the fallback category for miscellaneous corporate news.
2025-11-03 German
Cosmo Pharmaceuticals receives regulatory approval by the European Commission for Winlevi® in the EU, following on the positive CHMP opinion
Regulatory Filings Classification · 100% confidence The document is a press release announcing that Cosmo Pharmaceuticals has received regulatory approval from the European Commission for its product, Winlevi. It provides details on the approval, quotes from the CEO and a medical expert, and mentions the product's market availability. While it contains a link to a PDF attachment, the text itself is a standard corporate announcement regarding regulatory milestones, which falls under the 'Regulatory Filings' (RNS) category as it does not fit into specific financial reporting or governance categories.
2025-10-21 English
Cosmo Pharmaceuticals erhält nach positiver Stellungnahme des CHMP die behördliche Zulassung der Europäischen Kommission für Winlevi® in der EU
Regulatory Filings Classification · 100% confidence The document is a press release issued by Cosmo Pharmaceuticals announcing the European Commission's regulatory approval of their product, Winlevi. It details the regulatory milestone, provides quotes from leadership, and includes company background information. It does not fit into specific financial reporting categories like 10-K or IR, nor is it a simple report publication announcement (RPA) as it contains substantive news about product approval. Therefore, it is classified as a general regulatory announcement (RNS).
2025-10-21 German
Cosmo Pharmaceuticals announces regulatory approval of Winlevi® in South Korea
Regulatory Filings Classification · 100% confidence The document is a press release announcing the regulatory approval of a pharmaceutical product (Winlevi) in South Korea. It provides details on the product, the partnership with Hyundai Pharm, and a quote from the CEO. While it contains a link to a PDF attachment, the text itself is a standalone corporate announcement regarding business operations and regulatory milestones, which falls under the general regulatory announcement category as it does not fit into specific financial reporting or governance categories.
2025-10-07 English
Cosmo Pharmaceuticals gibt die behördliche Zulassung von Winlevi® in Südkorea bekannt
Regulatory Filings Classification · 100% confidence The document is a press release announcing the regulatory approval of a pharmaceutical product (Winlevi) in South Korea. It provides details about the drug, the partnership with Hyundai Pharm, and quotes from the CEO. It does not constitute a full financial report, audit, or proxy statement. Since it is a corporate announcement regarding business operations and regulatory milestones, and it includes a link to an external PDF attachment, it falls under the category of a general regulatory announcement or corporate news release.
2025-10-07 German

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.